MET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MetLife looks like a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing a constructive technical setup, analysts have been steadily lifting price targets, congress trading is net positive, and the latest news adds a practical retirement-product catalyst. At the current pre-market price of 81.96, MET still appears reasonably positioned for a long-term entry rather than being overextended. Given the user's impatience and willingness to buy now, I would rate it a buy.
MET is in a short-term bullish structure. The MACD histogram is positive at 0.0951, although it is mildly contracting, which suggests momentum is still positive but not accelerating strongly. RSI_6 is 50.709, indicating neutral momentum and no overbought condition. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports an uptrend across short, medium, and long horizons. Price is trading near the pivot at 81.871, above support at 79.182 and below resistance at 84.561, so the current level is a reasonable entry zone. The stock trend data also suggests a positive near-term bias, with a 70% chance of modest gains over the next day, week, and month.
["Analysts have been raising price targets across several firms, showing improving Street confidence.", "Keefe Bruyette lifted the target to 98 and kept Outperform.", "Wells Fargo, JPMorgan, Mizuho, Barclays, UBS, and Piper Sandler all raised targets recently.", "MetLife introduced the Guaranteed Income Program, adding flexibility to its retirement income offering.", "Congress trading shows 1 purchase and 0 sales in the past 90 days, signaling favorable political sentiment.", "Technical trend remains bullish with SMA_5 > SMA_20 > SMA_200."]
["Piper Sandler still maintains only a Neutral rating despite raising its target.", "Hedge funds are reportedly selling heavily, which is a negative institutional signal.", "Options positioning shows more puts than calls, suggesting cautious sentiment.", "MACD momentum is positive but contracting, so the trend is not accelerating strongly.", "Mizuho noted that the setup for life insurers remains challenging and that the group faces economic uncertainty."]
No usable latest-quarter financial snapshot was provided because of a data error, so I cannot review the actual quarter numbers directly. Based on the analyst commentary, however, Q1 results were strong enough for multiple firms to raise estimates and price targets. That implies the latest quarter likely showed acceptable growth and/or better-than-expected underwriting or operating performance, especially since analysts cited post-Q1 updates and favorable equity market performance.
The analyst trend is positive overall. Price targets have been revised upward repeatedly over the last few weeks, moving roughly from the low/mid-80s area to the mid-to-high 90s at several firms. Ratings are mixed but mostly constructive: Outperform, Overweight, Buy, and only one Neutral from Piper Sandler. The Wall Street pros view is bullish on balance, with the main con being that some firms still see limited upside or a challenging life insurance environment. Net takeaway: analysts are leaning positive and revising targets higher, which supports a buy view.
